BSEM Soars with $72.5M Q1 Revenue! ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
 |
| A message from Sideways Frequency |  BSEM: a cream of the crop biotech stock whose revenues are exploding and is on a mission to get on the NASDAQ! The future is regenerative medicine and BioStem Technologies (OTC: BSEM) is a growing company that is leading the way with innovation, exploding revenues, and breakthrough achievements. This growing medtech company is harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies in advanced wound care. BSEM is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. Over the last few months, BSEM has achieved a series of clinical, regulatory, and financial milestones. This includes breakthrough results from a diabetic foot ulcer would closure study, strong Q1 financial results, approval to advance a new clinical trial in treating venous leg ulcers, and a notice of allowance from the U.S. Patent and Trademark Office for two U.S. patent applications. BSEM has recently announced record preliminary net revenue of $72.5 million for Q1 2025. This is a 73% increase compared to $41.9 million in Q1 2024. The company also ended the quarter with cash on hand at $26.7 million, an increase from $22.8 million on December 31st, 2024. This was the strongest first quarter in the company's history! Over the past year Zacks Small Cap Research has been very bullish on BSEM and has been lifting its price target several times. After the company's last financial report, the firm gave BSEM a price target of $35.50. Could Zacks be ready to lift their price target once again? It should be also noted that BSEM is in the process of uplisting its stock to the NASDAQ stock exchange, which should improve access and liquidity for investors! Discover why BSEM is a company to put high on your radar, especially if Zacks lifts its price target again.
This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc. has received a fixed fee of $6000 from Sideways Frequency for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between May 19, 2025 and May 23, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM).
Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc
33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA
W: 877.6.STOCKS
StockEarnings.com
| | |
| |
Tidak ada komentar:
Posting Komentar